DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Data presented at the American Society of Hematology (ASH) Annual Meeting and Exposition showed the benefits of using Arginine (Arg) to supplement treatment of vaso-occlusive episdes (VOEs) in patients with sickle cell disease (SCD). While statistically insignificant, they observed a clinically relevant decrease in total parenteral opioid (TPO) and a shortened time to crisis resolution in both intervention groups treated with Arg compared with placebo.
In an interview with HCPLive, lead investigator and presenter Claudia Morris, MD, Childrens Healthcare of Atlanta, Department of Pediatrics, Emory University School of Medicine, shared a novel discovery found during the investigation that hadn’t been addressed in her talk at the conference.
“In our mitochondrial work, we actually uncovered a potential new mechanism of action (MOA) for hydroxyurea,” she explained, “because we saw that the patients who were on hydroxyurea had improved mitochondrial function and lower oxidative stress than the patients who are not on the hydroxyurea.”
education & researchDetermining Adherence to Quality Indicators in Sickle Cell Anemia Using Multiple Data SourcesINTRODUCTION: Advances in primary prophy...
education & researchIntelligence quotient in paediatric sickle cell disease: a systematic review and meta-analysisAIM: Sickle cell disease (SCD) is the co...
videos & visualsSickle Cell Breakthrough: Shauna’s Storyhttps://www.youtube.com/watch?v=Q-kXWV-s...
news & eventsCamp Sickle StarsCamp Sickle Stars is the only camp in th...
news & eventsStudy Confirms Safe Use of Opioids for Pain Control in Sickle Cell DiseaseThe most common cause of hospital admiss...
news & eventsRare Disease Day Symposium at the Quinnipiac Frank H. Netter MD School of MedicineSince 2015, the Frank H. Netter MD Schoo...
news & eventsSCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
send a message
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.